F2RL1 and esophageal cancer: Although it is uncertain whether nafamostat mesilate functions via suppressing PAR-2 activation [31], [32], it has shown promise in combination with gemcitabine in a phase I/II clinical trial for pancreatic cancer treatment [33], [34]–an encouraging example of how employing trypsin/PAR-2 activation blockade agents in combination with current chemotherapy might provide synergy in esophageal cancer treatment.